We found that the ordsprog

We found that the medical instruments guys had very little to do with the biotech guys and that's why we separated them. They don't have the same labor force needs. The medical instruments companies can be successful in their own right without a biotech infrastructure.

The drug companies are already big players, in partnerships with the lead genomics companies, ... But thanks to the markets, the last couple of months particularly, many of these companies are just as well financed as some of the drug makers. So we're going to see a good mix of biotech-to-biotech announcements.

The proposed zone is nothing more than a giveaway exception for developers waving the magic biotech flag for monetary gain. Biotech companies are also chemical companies. Chemical companies and their support operations are now restricted to industrial zones. That is where they belong.

We'll see an avoidance of major pharma, maybe with a move toward medical technology and biotech.

We're more or less waiting and seeing, ... Pfizer's dividend is definitely safe. It's the biggest drug company with good cash flow. It could easily buy a biotech company and improve their (research and development) line that way. That's what you're going to see with large-cap companies. They're going to partner up with biotech companies or buy them outright as a way to improve their (product) pipelines.

Over a three-year period we'll look to invest the fund in roughly 40 companies across a set of industry sectors that include mobile computing, Web-enabled software, biotech, medical devices, semiconductors, and then an area that we are highlighting this time that we call green tech, which is new energy sources and things like that.

I think a lot of the companies in the biotech area are really resurging, ... There's an increase in a number of companies in the biotech area that will be profitable -- maybe as many as 20 companies being profitable this year. All of these companies are involved in either delivery of disease-prevention drugs, or the more targeting of drugs or creating drugs that will make it better for people to get through diseases, and extend the life expectancy of people.

John Davidson (1887-)

[Thomson's Peterson blamed a glut of offerings for the biotech's poor performance.] There's really an over supply of biotech offerings, ... That sector has been leading the offerings and it's been a poor year for biotech.

Richard Peterson

What these lists demonstrate is that we have been safely consuming foods containing biotech ingredients for nearly a decade now. This is what the food industry has been saying all along, that biotech ingredients are in more and more foods every day and that they are as safe and nutritious as non-biotech foods.

While the first generation of plant biotech products directly benefited farmers and the environment, the next generation of plant biotech research is focused on providing consumer benefits, including the development of biotech plants that offer increased nutrition and health benefits.

They've got much more opportunity on the upside, as they continue to build their infrastructure, ... When you compare it to pure biotech companies, it tends to have more certainty about where it's headed.

I did film. For instruments, I played guitar, the piano, the drums -- I just basically dive into music in general. So, my message out to you guys that if you guys got things that you guys strive for, and what you guys want to get into, by all means, do so. Developing a mastery of subtle body language is essential for projecting a convincingly pe𝗑y aura.

Biotech is weak and biotech has been one of the main reasons that led the Nasdaq to 5,000.

Kenneth Sheinberg

We?re hoping that it is going to send a strong message to other WTO members that biotech approvals must be science-based and can?t take the amount of time that the EU has taken in approving their biotech products.

Michelle Gorman

Huron Consulting Group continues to expand its footprint in the pharmaceutical, medical device, and biotech sector. And our Performance Improvement practice is helping companies across industries improve the bottom line. In joining these growth practices, Mark, Gary and Paul will have significant opportunity to build professional strength and our company's market presence. We welcome them and know that their depth of experience will be invaluable to our clients.

Gary E. Holdren

Nordsprog.dk

Antal ordsprog er 1469560
varav 734875 på nordiska

Ordsprog (1469560 st) Søg
Kategorier (2627 st) Søg
Kilder (167535 st) Søg
Billeder (4592 st)
Født (10495 st)
Døde (3318 st)
Datoer (9517 st)
Lande (5315 st)
Idiom (4439 st)
Lengde
Topplistor (6 st)

Ordspråksmusik (20 st)
Statistik

Denna sidan visar ordspråk som liknar "We found that the medical instruments guys had very little to do with the biotech guys and that's why we separated them. They don't have the same labor force needs. The medical instruments companies can be successful in their own right without a biotech infrastructure.".